Exalenz Bioscience Ltd. announced the global launch of the BreathID Hp, a next generation device in the company's BreathID product line. BreathID Hp facilitates a 'test and treat' protocol, as recommended by the American College of Gastroenterology (ACG) guideline, by offering the most technologically advanced, fastest, highly accurate and specific, non-invasive test for H. pylori. According to the Centers for Disease Control, approximately two thirds of the world's population is infected with H. pylori, which is often undiagnosed and untreated.

It is the leading cause of peptic ulcers and is known to increase the risk of gastric (stomach) cancer. Exalenz also announced that it has formed in the U.S. a new direct sales and clinical support organization, designed to better address customer needs. The new strategy will provide improved support for the company's innovative, diagnostic system, intended for in-office and urgent care facility use.

BreathID Hp is a compact system that can fit on a small table or countertop. The new device is EMR (electronic medical records) compatible and Clinical Laboratory Improvement Act (CLIA) non-regulated -- essentially, any properly trained healthcare professional can operate it by simply following the screen-displayed directions. The BreathID Hp test is very easy to perform and takes approximately 10-15 minutes to complete and deliver results, thus enabling the physician to immediately prescribe treatment if necessary.

The system can also be used to test if the H. pylori bacteria has been eradicated. BreathID Hp provides a huge benefit for the health care system by reducing costs and repeat patient visits. Testing costs are reimbursable by Medicare, Medicaid and most other payers.